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INTRODUCTION 
 
In the later half of the twentieth century, gastro-esophageal reflux disease 
[GERD] emerged as the most common upper gastrointestinal disease of the western 
world. This disease is a major contributor to the rise in the war of endoscopy and acid 
suppression therapy. 
Epidemiolgic studies suggest a 3% to 4% prevalence of GERD in the general 
population with the preponderance of individuals having mild or moderate disease.  
Reflux esophagitis  results from the action of peptic juice on the esophageal mucosa.  
Reflux esophagitis  can occur in any age group  but is most common in the middle 
aged persons. Risk factors include hiatal -hernia, excessive vomitting and peptic ulcer 
disease.  The use of Non - steroidal antiinflammatory agents, alcohol abuse, cigarette 
smoking, diabetes,  systemic sclerosis  and pemphigus are also associated with gastro 
-esophageal reflux. 
Barrett’s esophagus, defined as the presence of the columnar metaplastic 
epithelium in the distal esophagus over a length of more than 2 to 3cm is usually 
considered to be a complication of long standing gastro-esophageal reflux disease 
[GERD] and is one of the major manifestations of GERD. 
Helicobacter pylori is a gram-negative, microaerophilic bacterium that 
inhabits various areas of the stomach and duodenum. It causes a chronic low-level 
inflammation of the stomach lining and is strongly linked to the development of 
duodenal and gastric ulcers and stomach cancer. Over 80% of individuals infected 
with the bacterium are asymptomatic. 
Helicobacter pylori has acquired great importance during the last two decades, 
after being recognized as an important pathogen that infects a great portion of the 
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human population. Helicobacter pylori is of major concern today because of its causal 
relationship with gastroduodenal diseases. The bacteria are prevalent worldwide and 
more than half of the world’s population are infected with H. pylori. 
Recently, it has been observed that  gastric colonization with H.pylori may also 
have beneficial effects for the human host. In this respect, the interest is in particular 
going to the potential preventive effect of H.pylori colonization on the development 
of gastro-esophageal reflux disease (GERD) and its complications such as Barrett’s 
esophagus and adenocarcinoma of the distal esophagus. If so, this will have a major 
impact on issues such as screening and treatment of H.pylori infections.  
By now, the potential role of H. Pylori in the development of GERD is a key issue 
in the treatment of patients with upper gastrointestinal disorders.  
GERD patients with concomitant H.pylori infection showed more severe gastritis 
in the antrum than in other parts of the stomach, such as corpus, fundus and cardia. 
Apart from a lower prevalence of GERD among H.pylori-positives, some also 
reported that if GERD is present in H.pylori-positive subjects, it may be less severe. 
This interesting note made us think to evaluate the various histomorphological 
changes seen in esophagus in cases of GERD and to correlate the findings with the 
status of  gastric H pylori colonization in those cases. 
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AIM & OBJECTIVES 
 
Aim: 
 To study the histomorphological changes  of esophagus in cases of GERD and 
its association with  gastric H.pylori infection. 
 
Objectives: 
 
1. To evaluate the  histomorphological profiles of  esophagus in cases of 
GERD. 
2. To evaluate the presence of gastric  H.pylori infection in these lesions.  
3. To correlate the histomorphological changes in the esophagus with the 
gastric H pylori status. 
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REVIEW OF LITERATURE 
 
Epidemiolgic studies suggest a 3% to 4% prevalence of Gastroesophageal 
reflux disease (GERD) in the general population with the preponderance of 
individuals having mild or moderate disease.  Reflux esophagitis  results from the 
action of peptic juice on the esophageal mucosa.  Reflux esophagitis  occurs in any 
age group  but is most common in the middle aged persons. Risk factors include hiatal 
-hernia, excessive vomiting and peptic ulcer disease.  The use of Non - steroidal anti 
inflammatory agents, alcohol abuse, cigarette smoking, diabetes,  systemic sclerosis  
and pemphigus are also associated with gastro -esophageal reflux.  Acid or alkaline 
reflux may be caused by an incompetent Lower Esophageal sphincter (LES) or altered 
esophagel motility. Incompetence of the LES is usually idiopathic, but it may also be 
attributable to alcohol ingestion, Cigarette smoking, or the use of therapeutic drugs 
(such as estrogens).  The LES tone is also lowered  during pregnancy and naso gastric 
intubations.   
Gastro-esophageal reflux disease affects patients of all ages, even in children 
and infants. It is equally present among men and women, but there is a slight male 
predominance of esophagitis and Barrett’s esephagus. Both genetic factors and 
environmental factors play a role in predisposition to GERD. Sonnenberg and Serag 
(1999). 
 The predisposing conditions to GERD include smoking, increased intra-
abdominal or intra-gastric pressure, including pregnancy, ascites, obesity and delayed 
gastric emptying. Motility disorders including diabetes, alcoholic neuropathies, 
achalasia and scleroderma also predispose to GERD. It also follows surgical 
procedures involving the lower end of esophagus such as esophagogastrostomy, 
Miller LS and Vinayek et al (1990). GER in infants and children complicates 
 5
congenital esophageal or gastric abnormalities.GER also associates with cystic 
fibrosis. (Button BM, Roberts.S, et al) (2005). 
 GERD is a multifactorial disorder. Most patients with GERD have a lower 
mean esophageal sphincter resting pressure. This allows acid to reflux into the 
esophagus, leading to the development of esophagitis. The inflammation further 
impairs the LES pressure, increasing acid exposure to the esophagus,  Biancani P, and 
Billetta, et al (1992). The nature and amount of refluxed material and the length of the 
time it remains in contact with the esophageal mucosa, as well as the number of reflux 
episodes, determine whether GERD develops. 
 GERD results from reflux of both acid and alkaline secretions. Acid when 
combined with pepsin or bile acids causes more severe damage. Fiorucci S, Santucci  
L, et al (1992). 
 The patients usually present with disease symptoms including heartburn, 
regurgitation, bitter tasting fluids in the mouth, dysphagia, odynophagia, nausea, 
vomiting, hiccups, angina like chest and hoarseness. It is especially common in 
preterm infants. Complications peak between the age of 50 and 70 years. Nebel OT 
and Fornes MF et al (1976). The severest complication is carcinoma developing in the 
setting of Barrett’s esophagus. 
GERD is the failure of the normal anti-reflux barrier to protect against 
frequent and abnormal amounts of gastro-esophageal reflux. GERD is complex, 
resulting from an imbalance between defensive factors protecting the esophagus (anti-
reflux barriers, esophageal acid clearance, tissue resistance) and aggressive factors 
from the stomach (gastric acidity, volume & duodenal contents). 
 The anti reflux barrier is an anatomically complex region including the 
intrinsic Lower esophageal sphincter, diaphragmatic crura, the intra-abdominal 
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location of the Lower esophageal sphincter,  the phrenoesophageal ligaments and the 
acute angle of HIS. 
 
ANATOMY OF THE GASTRO ESOPHAGEAL JUNCTION ILLUSTRATING 
THE MAJOR ELEMENTS OF THE ANTI-REFLUX BARRIER. 
 
 
 
 
 
 
 
 
 
 
 
The Lower esophageal sphincter, involves the distal 3 to 4 cms of the 
esophagus and at rest is tonically contracted. Liebermann – Meffert D, Alogower M, 
et al (1979). Lower esophageal sphincter is the major component of the anti-reflux 
barrier. Sloan S, Rade maker AW et al (1992). The proximal Lower esophageal 
sphincter  border is normally 1.5 to 2 cms above the squamo-columnar junction, 
whereas the distal segment, about 2 cm in length, lies within the abdominal cavity. 
This location maintains gastro-esophageal competence during the intra-abdominal 
pressure events. The Lower esophageal sphincter, maintains a high pressure zone by 
the intrinsic tone of its muscle and by cholinergic excitatory  neurons.  Dodds WJ, and 
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Dent J et al (1981). There is considerable diurnal variation in basal Lower esophageal 
sphincter pressure. It is lowest after meals and highest at night. 
 
The mechanisms of reflux are  
1. Transient lower esophageal sphincter relaxations. 
2. Swallow induced lower esophageal sphincter relaxations 
3. Hypotensive lower esophageal sphincter pressure. 
 
Transient lower esophageal sphincter relaxations are the most frequent 
mechanism for reflux in patients with healthy sphincter pressures. Transient Lower 
esophageal sphincter relaxations are independent of swallowing, are not accompanied 
by esophageal peristalsis, persist longer (>10 seconds) and are accompanied by 
inhibition of the crural diaphragm. Holloway RH, penagini R et al (1995). The 
dominant stimulus for transient Lower esophageal sphincter relaxations is distention 
of the proximal stomach by either food or gas. Mittal RK, Holloway RH et al (1995). 
Holloway RH,  kocyan p, et al (1991). 
Swallow induced lower esophageal sphincter relaxation: 
 Almost 5 to 10 % of reflux episodes occur during swallow – induced Lower 
esophageal sphincter relaxations. Most episodes are associated with defective or 
incomplete peristalsis. Mittal RK, Mc callum RW: 1987. Reflux during swallow 
induced Lower esophageal sphincter relaxation’s is more common with a hiatal 
hernia, this may be due to the lower compliance of the esophagogastric junction in 
hernia patients. Mittal RK and Lange RC et al (1987). Pandofino JE and shi G et al 
(2003). 
The second tier against reflux damage is the “oseophageal acid clearance”. 
There are two separate processes which are (i) Volume clearance: i.e the actual 
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removal of the reflux material from the esophagus (ii) Acid clearance; i.e the 
restoration of normal esophageal pH following acid exposure through titration with 
base from saliva & esophageal gland secretions. 
Esophageal peristalsis clears acid volume in both upright & supine positions.  
Helm and colleagus showed that one or two primary peristaltic contractions will 
completely clear 15 ml fluid bolus from the esophagus, Helm JF and dodds WS et al 
(1984). Primary peristalsis is elicited by swallowing. Secondary peristalsis initiated by 
esophageal distension from acid reflux, is much less effective in clearing the 
refluxate. Peristaltic dysfunction and hypotensive peristaltic contractions increases in 
frequency with severity of oesophagitis. Kahrilas and colleagues found that the 
prevalence of peristaltic dysfunction rose from 25% in individuals with  mild 
esophagitis to more than 50% in patiants with severe esophagitis. Kahrilas PS and 
dodds WJ et al (1986). 
Saliva is the second essential factor required for normal oesophageal acid 
clearance. Saliva is a weak base with a pH of 6.4 to 7.8 compared to gastric acid. 
Helm JF and Hogan WJ et al (1987). Hence saliva is ineffective in neutralizing large 
acid volume, it easily neutralizes the small amount of acid remaining in the 
oesophagus after severe peristaltic contractions. Helm JF and Doods WJ etal (1984).  
Modulation of salivation may contribute to GERD. Decreased salivation 
during sleep is the reason that nocturnal reflux episodes are associated with markedly 
prolonged acid clearance. Orr WC and Robinson MG et al (1987).  Xerostomia  
patients and cigarette smokers have a prolonged  esophageal acid clearance time due 
to hyposalivation. Korstem MA and Rosman As, et al (1991).  In addition to saliva, 
the aqueous bicarbonate rich secretions of the esophageal sub-mucosal glands dilute 
and neutralize the residual esophageal acid. Meyers RL and orlando RC, et al (1992). 
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Only a few subjects experience symptomatic GER and even fewer persons 
suffer GERD, due to a phenomenon of esophageal defense known as tissue resistance. 
Tissue resistance can be subdivided into pre-epithelial, epithelial, post-epithelial 
factors which act together to minimize mucosal damage from the noxious gastric 
refluxate. Orlando RC 1994. 
The pre-epithelial defense in the esophagus is poorly developed. The epithelial 
defense consists of both structural and functional components. Structural components 
include the cell membranes and inter-cellular junctional complexes of the  esophageal 
mucosa. The functional components of tissue resistance include the ability of the 
esophageal epithelium to buffer and extrude hydrogen ions. Intracellular buffering is 
accomplished by negatively charged phosphates and proteins as well as bicarbonate 
ions. The post-epithelial defense is provided by the  esophageal blood supply. Blood 
supply delivers oxygen, nutrients, bicarbonates and removes H+ ions and CO2, there 
by maintaining normal tissue acid –base balance. Hollowarth ME and smith M et al 
(1986). 
Gastric factors (volume and ingredients in the gastric refluxate) are potentially 
important in the production of reflux esophagitis. Gastric acidity determines the 
degree of potential mucosal damage of the refluxate. Acid and activated pepsin are the 
key ingredients of the gastric refluxate producing esophagitis. Acid alone causes 
protein denaturation. Acid when combined with even small amounts of pepsin, 
disrupts the mucosal barrier, resulting in increased H+ permeability, histologic 
changes and hemorrhage, Orlando RC and Bryson JC et al (1984).  
Along with acid and pepsin, duodenal contents may be injurious to the 
esophageal mucosa. Duodeno-gastric reflux into esophagus predisposes to 
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complications of GERD. Attwood SEA and DeMeester TR, et al (1978). Pellegrini 
CA and Wernly JA, et al (1978). 
 Delayed gastric emptying is a major factor contributing to GERD in some 
groups such as diabetic patients with autonomic peripheral neuropathy.  
Esophageal lesions in  Gastroesophageal reflux disease (GERD): 
Esophageal biopsies are used for evaluation of GERD. Microscopic changes 
of reflux may occur even when the mucosa endoscopically appears normal. The 
changes of basal cell hyperplasia and increased height of the retepegs both 
representing increased epithelial turn over of the squamous mucosa. 
Biopsies are taken in the area just distal to the  Z line to detect  carditis, just 
proximal to the Z line to detect the hyperplastic changes that are more predictive of 
the presence of GERD than more distally derived biopsies. 
There are generally four stages in the disease progression in cases of reflux 
esophagitis: 
(a). Acute ( necrosis, inflammation & granulation tissue formation) 
(b). Repair ( Basal cell hyperplasia and elongation of the papillae) 
(c). Chronic (fibrosis and formation of Barrett’s esophagus) 
(d). Complications ( Dysplasia and adenocarcinoma)  
HISTOLOGIC FEATURES IN GASTROESOPHAGEAL REFLUX DISEASE 
(GERD): 
¾ Epithelial hyperplasia 
¾ Basal zone hyperplasia. 
¾ Papillary elongation. 
¾ Ballooned  squamous cells  
¾ Vascular dilation. 
¾ Intra-epithelial eosinophills  
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¾ Intra-epithelial Lymphocytes. 
¾ Neutrophil infiltration  
¾ Mucosal ulceration / erosion 
 
Endoscopic features: 
Approximately one third of the patients with chronic gastroesophageal reflux 
disease  symptoms are endoscopically normal. Areas of patchy erythema and red 
streaks are seen in initial stages. Later, erosions and ulcers develop. Esophagus 
appears friable and diffusely reddened and hemorrhagic.   
 
ENDOSCOPIC GRADING SYSTEMS FOR OESOPHAGITIS 
SAVARY MILLER CLASSIFICATION 
Grade 0 : Not applicable 
Grade I : Single, erosive or exudative lesion on one  
longitudinal fold 
Grade II : Multiple erosions on more than one longitudinal  
fold 
Grade III : Circumferential erosions 
Grade IV : Ulcers, strictures or short oesophagus, isolated or  
associated with grades I to III 
Grade V : Barrett’s oesophagus + Grade I to III 
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Los Angeles Classification: 
GRADE A : One or more mucosal breaks confined to fold, < 5 mm 
GRADE B : One or more mucosal breaks > 5 mm confined to folds  
  but not  continuous between tops of mucosal folds. 
GRADE C : Mucosal breaks continuous between tops of 2 or more  
  mucosal  folds but not circumferential. 
GRADE D : Circumferential mucosal break. 
 
Helicobacter pylori 
Helicobacter pylorus is a spiral shaped micro-organism that has been 
recognized as the main causal agent of chronic gastritis and duodenal ulcers, and it is 
associated with the subsequent development of gastric carcinoma. In 1892 – Giulio 
Bizzozero gave the clear description of spiral bacteria on the gastric mucosa of the 
Dogs (McFarlane & Munro 1997). In 1896 - Saloon finds spirochetes in the stomachs 
of cats and mice.  In 1906 - First report of spirochetes on the surface of human 
gastric mucosa in histological slide of gastric carcinoma was reported. In 1921 - 
Luger discovers spirochetes in the gastric juice, and associates their presence with 
gastric cancer. In 1924 - Luck and Seth discovers urease in the human stomach, which 
they believe is  naturally occurring. It is now known that one of the virulence factors 
of  H. pylori is the urease enzyme, which splits urea into ammonia.  In 1938 – 
Doenges described spirochetes in the gastric glands of humans and primates (Macacus 
rhesus). In 1983 – Warren and Marshall described a S – shaped spiral bacteria which 
was associated  with surface epithelial inflammation.  In 1983 – The same authors 
were able to recover these pathogens in culture following  prolonged incubation with 
microaerophillic conditions: it was originally termed as “campylobacter pylori”. In 
1984 – Warren and Marshall reported that these bacteria were found in the antrum of  
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almost patients with chronic active gastritis, duodenal ulcer or gastric ulcer. In 1989 – 
Closer study of C.Pylori by Goodwin et al showed that C.Pylori possessed a number 
of chemotaxonomic properties of its own and renamed it as  Heliobacter pylori based 
on its spiral shape. In 1993 – National institute for Health consensus conference, 
Bethesda USA declared infection with Helicobacter pylori is an important cause of 
duodenal and gastric ulcers. In 1994 – The International Agency for Research on 
Cancer Classified H.Pylori as a  group 1 carcinogen (Julie Parsonnet 1996). In 1997 - 
Tomb et al. completed sequencing of the entire 1,667,867 base pair H. pylori genome. 
This assists in identifying new virulence factors for the infectivity of  H. pylori on the 
molecular level. In 2002 - The European Helicobacter Pylori Study Group published 
the Maastricht 2-2000.  In Consensus Report, suggesting a test-and-treat strategy for 
H. pylori in young  patients without atypical symptoms. This strategy advocates the 
use of non-invasive testing to evaluate for H. pylori and simply treating if found, even  
in the absence of ulcer disease documented on endoscopy. In 2005 - Warren and 
Marshall are awarded the Nobel Prize in Physiology / Medicine for their work on H. 
pylori and Peptic Ulcer Disease. This review into the history of H.Pylori shows that a 
lot of interest has been shown in studying this small organism in the past years. 
 H pylori is a curved S-shaped (spiral) flagellated (about 4 – 6) motile, gram 
negative bacterium. It measures approximately 0.5 microns in width and 2-3 microns 
in length (Goodwin et al (1985). It has a unique and unusual fatty acid 3 –
hydroxycatadecanoic acid on the cell membrane (which is not present in 
Campylobacters). Therefore it was classified into a separate genus Helicobacter 
(Lambert et al (1987): Goodwin et al (1989). Motility is darting and rapid due to 
multiple, sheathed flagella with terminal bulbs and its helical morphology: this 
facilitates movement through viscous environments such as mucus (Hazell et al 
 14
(1986): Lee A et al (1988). It is non-sporulating and grows at 37 degrees C under 
microaerobic conditions (Megraud F (1989). 
The remarkable property of this organism is its ability to split urea, which is 
not seen in other Helicobacters affecting man (Langerberg et al (1984). When 
incubated in oxygen on prolonged culture or when exposed to bismuth salts and 
antibiotics, it transforms morphologically from spiral to coccoid form (Dhawan et al 
(1997). 
Two important mechanisms are urease activity and the presence of sheathed 
flagella on the outer surface of the bacterium, which enable bacterial transfer through 
the acidic gastric lumen into the viscous epithelial mucus layer (Suerbaum S. et al 
1993). The flagellar filament consists of two different proteins,  FlaA and FlaB, which 
are both essential for motility. (Josenhans C, and Labinge A, et al 1995)  Allelic 
disruption of flaA and flaB, the genes encoding for the FlaA and FlaB proteins, 
evoked mutant H. pylori strains with reduced motility, that were unable to colonize 
gnotobiotic piglets (Eaton K, Suerbaum S et al 1996) .  Functional studies revaled that 
motility is dependent on viscosity and pH (Hazell S, Lee A et al 1986).   
H. Pylori is a helix-shaped Gram-negative bacterium, about 3 micrometres 
long with a diameter of about 0.5 micrometre. It is microaerophilic; it requires oxygen 
although at lower concentration than is found in the atmosphere. It contains a 
hydrogenase which can be used to obtain energy by oxidizing molecular hydrogen 
(H2) that is produced by intestinal bacteria. It produces oxidase, catalase, and urease. 
H. Pylori is a spiral or curved micro-aerophilic Gram negative rod, equipped 
with 4-6 flagellae at one end. H.pylori possesses unipolar, sheathed flagella that, with 
their spiral shape, allow the organism to move quickly from the lumen of the stomach, 
where pH is low through the mucus layer to an area where pH is near neutral to 
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permit optimal growth. H.pylori also prefers the antrum, where parietal cells are 
absent or scanty. It has the ability to survive in the stomach despite the mucosal 
immune response. The immune response of the GIT is only successful against 
bacteria such as H.Pylori, which remain in the lumen. The low pH in the stomach 
lumen may further impair the effect of IgA antibodies against H.Pylori. 
The important feature of H.pylori might be due to the specific binding of 
H.pylori to the gastric cells of the surface and foveolar type. About 20% bacteria are 
attached in this way, sometimes through an adhesion pedestal. Narikawa S, and Imai 
N, (1990).  
Upon entering the stomach, H. Pylori heads toward the mucus layer which is 
rich of high-molecular-weight mucins, urea and sodium bicarbonate.  After 
penetrating this viscous layer, adherence of the bacteria to the nearby epithelium is 
facilitated by formation of bacterial pedestals (Caselli M and Figura N etal 1989).  
 The affinity for specific receptor structures presented by different epithelial 
cells may affect the distribution of H. pylori colonization through out the stomach.  
Apart from motility and adhesion, survival in the gastric acid environment is 
facilitated by enzymatic activity of the bacteria.  The major enzyme produced by H. 
pylori is urease. Adhesion may restrict bacterial colonization to the stomach, but may 
also contribute to tissue damage. H.pylori also colonizes heterotopic or metaplastic 
gastric epithelium outside the stomach. This includes patches of metaplastic gastric 
epithelium in the duodenal bulb of patients with duodenal ulcers. Wyatt J, and 
Rathbone BJ et al (1990). Barrett’s epithelium in the oesophagus of the patients with 
chronic acid reflux. Loffeld RJ, Ten Tije BJ, (1992). Ectopic gastric epithelium in 
Meckel’s diverticula can also be colonized. De cothi GA, Newbold KM, (1989). 
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Epithelial damage plays a key role in the induction of H.pylori colonization, as 
it may enable the bacterium to obtain essential nutrients such as iron.  It is however 
also a key factor in the establishment of disease during long – term colonization, and 
probably also a factor in the prevention of GERD.  Epithelial damage is not only the 
result of ammonia production.  Leunk et al, described that supernatants of H. Pylori 
cultures could induce vacuoles in eukaryotic cells (Leunk RD, Johnson PT etal 1988).  
Further research revealed that expression of the responsible vacuolating cytotoxin A 
occurred in only 50% of H. pylori strains even though the gene encoding for this 
cytotoxin was present in all strains.  
 
 Expression of VacA is considered a marker for more virulent strains with 
higher cytotoxicity. Different alleles were recently described for the vacA gene, they 
differ in their middle regions (two variants: m1 and m2) and signal sequence regions 
(four variants: sla, slb, slc, and S2).  Although eight genotypes are thus theoretically 
possible, strains containing VacA, S2ml have not been observed.  Strains containing 
slml are high toxin producers, whereas s2m2 are low producers.  Patients with peptic 
ulcer disease are more often infected with strains containing the s1 genotype 
(Atherton JC, Cao P et al 1995). 
 
 Strains carrying the CagA+ phenotype thus seem to be more virulent than 
CagA-strains.  Unlike the vacA gene, the cagA gene is not conserved in all H. pylori 
strains. In developing countries the prevalence of cagA+strains is  higher.  The cagA 
gene is 30kb marker for a pathogenicity island, containing several genes including 
picA and picB (Tummuru MKR, Sharma SA, et al 1995).  Transcription of both these 
genes is linked to that of cagA and lack of transcription of one gene causes lack of 
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transcription of all downstream genes.  Mutations in the cagA gene preserves the 
virulence of cagA + H. pylori strains, whereas mutations in picA or picB diminish the 
cytotoxic activity of the strain. The virulence of cagA + strains thus essentially 
depends on expression of picA and picB.  
 
Strains that contain vacA sl, cagA + or ice Al are considered highly 
pathogenic and are strongly associated with more severe gastritis and its 
complications such as peptic ulcer disease, whereas type vacA s2ms, cagA-iceA2 are 
considered less pathogenic. More virulent strains also have a greater effect on acid 
production and therefore may play a more significant role in GERD. 
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PROPOSED NATURAL HISTORY OF H.PYLORI INFECTION 
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ASSOCIATION OF H. PYLORI WITH BARRETT’S OESOPHAGUS 
In a meta – analysis of 26 case – control and cross – sectional studies, several 
of them being preliminary reports, 562 of 1426 GERD patients were H. pylori 
positive (39%) compared with 1009 of 2010 control subjects (50%) (O’Connor HJ, 
1999).  
 Reflux disease results from the interaction between acid production, lower 
esophageal sphincter pressure, esophageal clearance and gastric emptying.  H.  pylori 
may affect several of these factors.  In particular acid production can be affected in H. 
pylori – positive subjects by various mechanisms.  Some individuals respond to H. 
pylori colonization with an exaggerated gastrin response, leading to increased acid 
production and limitation of H. pylori gastritis to the gastric emptying (Gillen D El-
Omar EM, et al 1998).  
 In many others however, gastric acid production is impaired due to several 
factors, including the release of substances such as the VacA protein, which directly 
inhibits parietal cell function and bacterial urease activity generating large amounts of 
acid – buffering ammonia.  As a results of these factors, H. pylori gastritis extends 
into the gastric corpus where mucosal inflammation further impairs acid production, 
among others by the generation of interleukin-1, which has a 100-fold stronger acid – 
suppressive capacity than proton pump inhibitors.  Most importantly however, more 
than 50% of the H. pylori positive subjects eventually develop chronic atrophic 
gastritis.  This results in a loss of parietal cells and thus a further impairment of acid 
production. (Kuipers EJ, Uyterlinde AM, et al 1995)  These factors which lead to 
persistent decrease in acid production  can explain why H. pylori may protect against 
GERD.   
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THE POSSIBLE ROLE OF HELICOBACTER PYLORI IN 
GASTROESOPHAGEAL REFLUX DISEASE 
A variety of abnormalities contribute to the development of gastroesophageal 
reflux disease (GERD) including transient lower esophageal sphincter relaxation, low 
esophageal sphincter pressure, presence of a hiatal hernia, diminished esophageal 
clearance of refluxed gastric contents, and alterations in esophageal mucosal 
resistance.  Helicobacter pylori infection clearly plays a role in the Pathogenesis of 
Peptic ulcer disease and mucosa associated lymphoma of the stomach and is a definite 
risk factor for distal gastric cancer.  The role of H. pylori infection in 
gastroesophageal reflux disease remains controversial and incompletely understood. 
Although H. pylori infection does not cause reflux disease, circumstantial evidence 
suggests that it may protect against the development of gastroesophageal reflux 
disease and its complications in some patients. The most likely mechanism where by 
H.pylori infection protects against gastroesophageal reflux disease is by decreasing 
the potency of gastric refluxate in patients with corpus predominant gastritis. (Flak 
GW, USA DH 44195). 
SEVERITY OF GASTROESOPHAGEAL REFLUX DISEASE  IN INFECTED 
AND NON-INFECTED H.PYLORI PATIENTS 
 It has been postulated that H.pylori infection, if in a body – predominant 
pattern, would lead to reduced gastric acid, resulting in a reduced acid content in any 
potential refluxate. In fact, in patients with esophagitis, those not infected with 
H.pylori had more grade A esophagitis, a finding contrary to the postulate of less 
severe gastroesophageal reflux disease with infection. Zentilin et al also noted similar 
comparisons between H.pylori infected and non-infected gastroesophageal reflux 
disease patients. 
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The current results are compatible with the findings by Moayeddi et al. In a 
well –designed study H.pylori infected gastroesophageal reflux disease patients did 
not experience any increase in relapse of moderate to severe gastroesophageal reflux 
disease symptoms post-eradication. Tefera et al also found no change in 
gastroesophageal reflux disease patients 12 weeks after eradication of this infection 
and infact, schwizer et al found that eradication positively affected gastroesophageal 
reflux disease relapse. 
Bowrey et al examined gastric patterns in gastroesophageal reflux disease 
patients and found gastritis of the cardia commonly regardless of whether patients 
were infected or not with H.pylori. However M.Newton et al found that when 
H.pylori colonised the gastric antrum it was usually found in the gastric fundus. They 
concluded that H.pylori is not more common and its distribution does not differ in 
those with esophagitis compared with control subjects and is therefore unlikely to be 
aetiologically important in these patients. H.pylori however can colonise Barrett’s 
epithelium. 
In another study it was concluded that H.pylori colonisation protects against 
Barretts Esophagus and that the association may be atleast partially mediated through 
gastroesophageal reflux disease. 
In another study the frequency of H.pylori was low in esophageal biopsy 
specimens (15%) as well as in gastric biopsy specimens (35.6%). 
Specialised metaplastic epithelium was not colonised by the bacteria and the 
presence of H.pylori in the esophagus was always associated with gastric infection. 
This finding has been reported previously in retrospective studies indicating that 
H.pylori colonisation of Barrett’s mucosa is probably a consequence of gastric 
infection. Francoual S, Gruppo (1990). 
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When H.pylori was identified histologically in the gastric fundus or in the 
esophagus it was always found in the antral biopsy specimens also. This study has 
shown no difference in the prevalence of H.pylori in patients with esophagitis 
compared with controls some have reported improvement in reflux after eradication 
of H.pylori Francoual et al (1990). 
Francoual et al suggested that in those with active esophagitis H.pylori was 
found more commonly in the proximal stomach. Others have not found an association 
(Johnston DA and Goudie B et al) (1994). 
In this study when H.pylori was present it was usually found in both the 
gastric antrum and gastric fundus, suggesting that H.pylori colonises the whole 
stomach. (Barthel JS) (1988). though others report a higher frequency of H.pylori in 
the gastric antrum than the fundus (Bayerdroffer E) (1992). 
H.pylori has been shown to colonise the gastric epithelium of Barrett’s 
esophagus. Hazell SL, 1988. Talley NJ 1988. 
More recently justin et al, showed that in 30 patients with Barrett’s esophagus 
there was a higher colonisation rate in the metaplastic – esophageal mucosa when 
esophagitis was also present. Justin TA 1988. 
Helicobacter pylori may be found in Barrett’s mucosa (Paull G et al 1988) but 
apparently only when also present in the stomach, thus providing additional evidence 
for the presence of reflux in this condition. 
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BARRETT’S OESOPHAGUS (BE): 
 Norman Barrett first described this entity in 1950 (Spechler SJ 1996). Barrett’s 
esophagus, defined as the presence of columnar metaplastic epithelium in the distal  
tubular esophagus over a length of more than two to three centimeter, is usually 
considered a complication of long-standing gastroesophageal reflux disease. 
 The current definition states that to say BE, both endoscopic and histologic 
criteria to be met. The endoscopic component requires the presence of columnar 
mucosa identified endoscopically by its salmon pink colour, extending proximally 
from the Gastro-esophageal junction into the tubular esophagus. (Spechler SJ 2002). 
The histologic component requires that the biopsies taken from the endoscopically 
identified columnar pink mucosa contain metaplastic or intestinalized columnar 
epithelium with goblet cells (Sampliner RE 2002). 
 Barrett esophagus is divided into long segment BE (LSBE) in which the 
columnar mucosa extends 3 cm or more above the GEJ and short segment BE 
(SSBE), in which the specialized columnar epithelium is restricted to < 2 to 3 cms 
above the GEJ. BE develops in upto 44% patients with reflux esophagitis. It has a 
bimodal age distribution with one peak at 0 to 15 years and another at 40 to 80 years. 
 BE is an acquired metaplastic change that results from long standing GERD. 
Multi-potential immature stem cells differentiate into various epithelial types, 
including columnar epithelium which is more resistant to acidic digestion and which 
is able to regulate more rapidly than the native squamous epithelium. 
 The development of BE is a multi-step process with atleast 3 distinct phases. 
During the initiation phase genetically predisposed individuals, suffering from GERD 
develop reflux esophagitis. This leads to the formation of a metaplastic epithelium 
with features of intestinal columnar epithelium. 
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 During the formation stage, the metaplastic epithelium, which continues to be 
exposed to the refluxate, establishes its presence and occupies a variable surface area 
of the distal esophagus. This results in the oral migration of the squamocolumnar 
junction over time (Hamilton SR 1977). 
 A long and multifaceted progressive phase follows, during which the 
metaplastic epithelium either remains dormant and clinically insignificant or 
progresses to dysplasia and invasive adenocarcinoma. 
Gross and endoscopic features: 
 BE appears beefy red and velvety, contrasting with the lighter pink coloured 
smooth squamous mucosa. The  Squamocolumnar Junction (SCJ) often lies within 30 
cms of the incisor teeth and often co-exits with a hiatal hernia, stricture, diffuse 
esophagitis or esophageal ulcers. 
Patterns of BE: 
9 Circumferential, islands and finger-like projections or tongues. 
9 Patients with SSBE have short tongues or patches of red mucosa lying 
< 2 cms above the GEJ 
Endoscopy biopsy areas: 
1. The stomach just distal to the upper end of the gastric folds, 
particularly along the lesser curvature. 
2. 1 to 2 cm above the GEJ. 
3. Tongues of mucosa or irregular areas above the SCJ 
4. The SCJ and squamous epithelium of the native esophagus. 
 Biopsies at the upper end of the gastric folds, may allow one to determine 
whether there is gastritis, particularly HP induced gastritis and possibly intestinal 
metaplasia. 
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Histology of Barrett’s esophagus (BE): 
The definition of Barrett’s esophagus requires histologic confirmation of 
intestinal metaplasia in biopsies taken from the columnar regions of the esophagus. 
The metaplastic BE epithelium resembles either small intestinal absorptive cells 
(complete intestinal metaplasia) or incomplete intestinal metaplasia (resembling 
colonic epithelium). In the latter, the cells lack a distinct brush border and associated 
enzymes that normally characterize small intestinal absorptive cells.  
The majority of the intestinal columnar cells are so-called intermediate, 
principal or pseudoabsorptive cells that have characteristics of both absorptive and 
secretory cells. H.pylori may be found in some of the patients with BE but only when 
it is also present in the stomach. It may contribute to the severity of the inflammation 
seen in BE. 
Intestinal metaplasia at the Gastro-esophageal Junction (GEJ) is either SSBE, 
which has a cancer risk at most of 0.5% per year or intestinal metaplasia of the 
proximal stomach, which appears to have a substantially smaller risk for malignancy. 
These two conditions cannot be distinguished reliably because the morphologic & 
histochemical features of gastric & esophageal intestinal metaplasia resemble one 
another and because the gross landmarks used to identify the GEJ do not have the 
precision necessary to localize the mucosa. 
Squamous metaplasia develops in the distal esophagus following treatment of 
BE. It appears as a normal appearing neosquamous epithelium or as a multilayered 
immature squamous metaplasia. The neosquamous epithelium appears in areas 
previously occupied by BE, often appearing as squamous islands surrounding the 
Barrett epithelium. Squamous metaplasia resembling that seen in the uterine cervix 
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develops at the GEJ in patients with BE. It usually appears as a pseudostratified 
epithelium; cilia are often present on the luminal surface.  
DYSPLASIA IN BARRETT’S ESOPHAGUS: 
 Histopathologically, the development of an adenocarcinoma appears to be 
preceded by epithelial dysplasia. Often, surrounding an adenocarcinoma in Barrett’s 
esophagus, dysplastic changes can be found.  Furthermore, longitudinal follow-up 
studies have documented the gradually increasing severity of dysplasia eventually 
resulting in adenocarcinoma.  These observations suggest, that dysplastic changes 
might be taken as early indicators of incipient malignancy.  
 Dysplasia is defined as neoplastic proflieration within eipithelial glands 
without affecting the basement membrane.  Dysplasia in Barrett’s esophagus is 
classified as low or high grade in fashion comparable to dysplasia in inflammatory 
bowel disease. (Riddell RH: Goldman et al 1983) This implies that the grade of 
dysplasia should be determined by the features of the most dysplastic region, either 
surface or base.  
 The criteria for the grading of dysplasia in Barrett’s esophagus are cited from 
Haggitt et al (Haggitt RC 1994).  
¾ Low grade dysplasia. 
The crypt architecture tends to be preserved and distortion, if present is mild; 
the nuclei may be stratified, particularly near the base of the crypts, but the 
stratification does not reach the apical surfaces of the cells; nuclei are enlarged, 
crowded, and hyperchromatic; mitotic figures may be present in the upper portion of 
the crypt; and goblet and columnar cell mucus is usually diminished or absent, but 
goblet cells in which the mucus droplet does not communicate with the surface may 
be observed.  The abnormalities extend to the mucosal surface.  
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¾ High grade dysplasia. 
Distortion or crypt architecture usually is present and may be marked; it is 
composed of branching and lateral budding of crypts, a villiform configuration of the 
mucosal surface, or intraglandular bridging of epithelium to form a cribriform pattern 
of ‘back-to-back’ glands, nuclear abnormalities are present as in low grade dysplasia, 
but stratification reaches the crypt luminal surface, there may be a loss of nuclear 
polarity, i.e. not perpendicular to the basement membrane, and the nuclei often vary 
markedly in size, shape, and staining characteristics.  Goblet and columnar cell mucus 
is usually absent.  The abnormalities extend to the mucosal surface.  In addition, it 
might be difficult to reliably exclude (micro) invasion within the lamina propria in 
cases of high grade dysplasia.  In fact, beginning microinvasion, defined by an 
irregular epithelial stromal interface, is considered an integral part of high grade 
dysplasia in Barrett’s esophagus (Cameron AJ: 1997) Another phenomenon that needs 
attention is the discrimination of reactive changes from true dysplasia.  Especially 
when ulcertation is present one should be cautious in the interpretation of cellular 
atypia.  In these cases it is best to wait for repeat biopsies after adequate anti-reflux 
therapy.  Reactive changes may lead to mild nuclear and cellular atypia, which might 
be classified as low grade dysplasia.  Reactive cytonuclear changes are usually mainly 
present in the deeper parts of the glands, and do not involve the mucosal surface.  This 
feature can be used to discriminate reactive atypia from true dysplasia.  However, in 
case of doubt the classification ‘indefinite for dysplasia’ should be applied.  
Short – segment Barrett’s esophagus: 
Intestinal metaplasia at the gastro-esophageal junction has gained great 
interest recently, since it might be involved in the rapid increase of adenocarcinomas 
in this region over the past 20 years (Blot WJ et al 1991).  The significance of short-
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segment Barrett’s esophagus (intestinal metaplasia limited to the distal 3 cm of the 
tubular esophagus), which is increasingly being found both endoscopically and 
histologically, remains controversial.  In most cases it seems to be associated with 
reflux diease.  At present, the risk of developing dysplasia and adenocarcinoma due to 
short-segment Barrett’s esophagus is considered to be low (Weston AP : Krmpotich P 
et al (1996). 
 The prevalence of dysplasia appeared two times higher in long – segment 
Barrett’s esophagus, than in short segments of Barrett’s esophagus (Hirota WK: 
Loughney TM et al 1999)  Therefore, agreement exists that patients with short 
segment Barrett’s esophagus require surveillance, until long –term follow up studies 
have clarified  its cancer risk.  
INTESTINAL METAPLASIA AT THE GASTROESOPHAGEAL JUNCTION 
 Esophageal adenocarcinoma is strongly correlated with Barrett’s esophagus.  
Cameron et al (1995) found a 100% correlation between esophageal adenocarcinoma 
and the presence of Barrett’s esophagus.  The same authors reported that in patients 
with a junction adenocarcinoma, which was defined as a tumour centered less than 2 
cm from the junction,  Barrett’s esophagus was present in about half of cases.  They 
concluded that adenocarcinomas of the gastro-esophageal junction are associated with 
short and long segments  of Barrett’s esophagus.  Intestinal metaplasia at the gastro–
esophageal Junction was also observed by others (Spechler SJ: Seroogian JM: et al 
1994). 
 Intestinal metaplasia of the gastroesophageal junction is found in 
approxitamely 10-40% of patients without long segments of Barrett’s mucosa 
(Nandurkar S: Talley NJ: 1997).  Spechler et al (1994).  Reported that 15-20% of 
adults undergoing elective upper endoscopy had segments of intestinal metaplasia at 
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the  gastro-esophageal  junction, which were not recognized by endoscopy.  Trudgill 
et al (1997), also concluded that intestinal metaplaisa at the junction is a common 
finding.  In general, it is found in the setting of gastritis or related to gastro-
esophageal reflux disease.  Histologically it may be difficult to discern a short-
segment Barrett’s esophagus from (focal) intestinal metaplasia of the gastric cardia.  
ROLE OF HELICOBACTER PYLORI IN THE METAPLASIA OF (CLO) 
COLUMNAR-LINED ESOPHAGUS:  
 There is much interest in the role of Helicobacter pylori (HP) in the 
pathogenesis of columnar-lined esophagus (CLO) and its progression to 
adenocarcinoma.  There is an increasing body of evidence linking so-called ultra-short 
segment CLO (USSCLO; now better termed intestinal metaplasia {IM} of the cardia) 
with HP infection and intestinal metaplasia elsewhere in the stomach (Morales TG, 
Sampliner RE, 1997).  Conversely, there is increasing evidence of a reciprocal 
relationship between HP and traditional / classical CLO and short segment 
CLO(Blaser MJ. 1998).  It has been suggested that gastric infection, especially 
pangastric, with cag-A positive strains of HP may be protective against CLO. It may 
be therefore that the dramatic changes in the prevalence of CLO and esophago-cardiac 
adenocarcinoma are related to alterations in the prevalence of gastric HP infection.  It 
has been proposed that a crucial determinant of the predominant pathology of the 
upper gastro-intestinal tract, in evolutionary and epidemiological terms, is the time of 
acquisition of HP infection.  Thus ameliorating socio-economic circumstances and the 
widespread use of antibiotics may account for a dramatic reduction in HP gastritis in 
childhood and early adulthood in Western communities over the past few decades.  
This, in turn, may help to explain the proximal movement in the prevalence of gastric 
cancer and the increase in GERD, columnar-lined esophagus and esophageal 
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adenocarcinoma.  Perhaps the most important pathogenic factor here is that highly 
prevalent helicobacter infection (especially cag-A positive HP), often contracted at a 
young age, leads to pan gastritis and a reduction in acid output from the stomach 
because of the destructive inflammation within the gastric fundus.  The reduction in 
acid in turn may reduce the propensity to acid-induced reflux esophagitis and thus 
reduce the incidence of CLO – type metaplasia.  Indiscriminate eradication of HP may 
not be a sensible strategy (at least for esophageal disease) and there must be careful 
consideration of potential risks as well as benefits of HP eradication policies.  
Useful pathological criteria for the diagnosis of dysplasia in columnar-lined 
esophagus.  
Low grade dysplasia consists of mild or moderate adenomatous dysplasia, 
enlarged, crowded, hyperchromatic and ovoid nuclei. Mitotic activity may be 
substantial and atypical mitoses may be present  Nuclear stratification is often present. 
Architectural changes, include villosity. There is loss of the basal – luminal 
maturation / differentiation axis. 
High-grade dysplasia consists of  severe adenomatous dysplasia . Nuclei are 
enlarged, usually spheroidal, and have an open chromatin pattern with prominent 
nucleoli. Mitotic activity may be substantial and atypical mitoses are usually present. 
Nuclear stratification may be present but there is usually pronounced cellular 
disorganization. Architectural changes, including villosity, glandular budding and 
complex glandular structures, is usually present. There is loss of the basal luminal 
maturation/ differentiation axis.  
 Patients with BE develop hyperplastic polyps, squamous papillomas, dysplasia 
and rarely adenomas. The major importance of BE lies in the propensity to develop 
into an adenocarcinoma. 
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COMPLICATIONS OF GASTROESOPHAGEAL REFLUX DISEASE: 
 
 Increasing age is an important factor in the prevalence of GERD 
complications.  (Collen M J, et al 1995). GERD is associated with considerable 
morbidity and complications such as esophageal ulceration’s, peptic strictures and 
Barrett’s esophagus. Complications peak between the ages of 50 and 70 years (Nebel 
OT, et al 1976). The severest complication is carcinoma developing in the setting of 
Barrett’s esophagus.  
 The mucosal changes of reflux esophagitis range from erosions, superficial 
ulcers, and extension of the inflammatory process, leading to fistula formation. 
 Erosions are superficial lesions that remain confined to the lamina propria and 
muscularis mucosae sparing all but the most superficial layers of the submucosa. The 
necrosis, hemorrhage, and inflammation associated with ulcers, extend deeper into the 
underlying  submucosa or muscularis propria. The epithelium close to erosions or 
ulcers often contains neutrophils, eosinophils, and many lymphocytes. The erosions or 
ulcers often contain granulation tissue, an inflammatory exudate, and fibrinoid 
necrosis in the ulcer base. Lymphoplasmacytic infiltrates, often forming lymphoid 
aggregates, tend to cluster around erosions and ulcers. Epithelium at the ulcer margin 
is usually attenuated. Marked basal cell hyperplasia may occupy the entire mucosal 
thickness and there may be marked acanthosis. These changes may be accompanied 
by occasional bizarre epithelial or stromal cells. 
 Erosions or ulcers may be isolated or confluent; they commonly coexist with 
one another. The damaged mucosa present in reflux esophagitis becomes prone to 
secondary infections. 
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 If appreciable ulceration has occurred, longitudinal ridges with crests develop. 
The ridges consist of hyperplastic, hyperkeratotic, acanthotic, squamous epithelium 
and extensions of lamina propria; the troughs represent linear ulceration. The 
alternating ridges and ulcers end abruptly at the cardia; they usually taper away 
gradually into the surrounding squamous mucosa as one proceeds proximally, 
Pyogenic granulomas may develop. 
 
 Esophageal peptic ulcers also develop in the setting of reflux esophagitis; they 
resemble peptic ulcers occurring elsewhere. These may erode through the muscular 
layers, resulting in perforation. Peptic ulcers appear large, oval, and well 
circumscribed with elevated borders and deep necrotic centers. As these heal, 
strictures develop. This occurs in about 10% of patients with severe reflux 
esophagitis. Fibrosis is usually present and may extend into the submucosa or beyond, 
sometimes extending into the periesophageal tissues. Although peptic strictures nearly 
always involve the distal esophagus, they occasionally develop more proximally. 
Proximal strictures average 2 to 4 cm in length. Extensive strictures complicate 
fulminant reflux esophagitis as well as nasogastric intubation in patients with reflux 
esophagitis or Zollinger –Ellison syndrome. 
 
 A large  retrospective European study with 6.5 years of follow –up found 
complications in 21.6% of patients, including 13 patients with esophageal ulcers, 15 
with strictures, and 45 patients with Barrett’s epithelium (Brossard E et al  1992). 
However, these data  contrasted with other studies in which no patients with erosive 
esophagitis developed Barrett’s  esophagus in a 2-year U.S. trial  (Spechler SJ 1992) 
and in which stricture  was reported in only 0.26% of 3800 French patients (Rejeb 
MB 1992) over a 12-year period. 
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MATERIALS AND METHODS 
 
 
 In our study 150 cases of patients presenting with symptoms of GERD 
attending medical gastroenterology outpatient department of Tirunelveli Medical 
College Hospital  and a private gastroenterology    clinic were included.  
 
 The patients were evaluated clinically and subjected to upper Gastrointestinal 
(GI) endoscopy The findings in the upper gastrointestinal (UG) endoscopy were 
recorded and biopsy were taken from the esophageal lesions.  
 
 Subsequent   gastric antral biopsies was also done in these cases during the 
same sitting The samples were fixed in 10% neutral buffered formalin and 
processed in routine manner.  
 
 4 µ (micron) sections were cut from both the tissues and stained with 
Haematoxylin and eosin. Gastric biopsy were also stained with Warthins starry 
stain to evaluate the presence of H. Pylori.  
 
 The demographic data were recorded  in a Proforma.  
 
The histopathological changes of esophagus were recorded.  The findings 
were correlated with the H. Pylori status of the gastric antral biopsies.  
 
 The gastric antral biopsies were stained with haematoxylin and eosin and 
graded according to the modified sydney system of classification.  
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STANDARD HEMATOXYLIN AND EOSIN 
STAIN FOR PARAFFIN SECTIONS 
 
METHOD 
1. Dewax sections, hydrate through graded alcohols to water. 
2. Remove fixation pigments if necessary. 
3. Stain in an alum hematoxylin of choice for a suitable time  
4. Wash well in running tap water until sections ‘blue’ for 5 minutes or less. 
5. Differentiate in 1 per cent acid alcohol (1 per cent HCI in 70 per cent 
alcohol) for 5-10 sec. 
6. Wash well in tap water until sections are again ‘blue’ (10-15 minutes), or 
7. Blue by dipping in an alkaline solution (e.g. ammonia water), followed by 
a 5-min. Tap water wash. 
8. Stain in 1 per cent eosin Y for 10 min. 
9. Wash in running tap water for 1-5 min. 
10. Dehydrate through alcohols, clear and mount. 
 
RESULTS 
 
Nuclei    : blue/black 
Cytoplasm   : varying shades of pink 
Muscle fibers   : deep pink/red 
Red blood cells  : orange/red 
Fibrin    : deep pink. 
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WARTHIN – STARRY METHOD FOR SPIROCHETES 
(Warthin & Starry 1920) 
SECTIONS 
Formalin-fixed, paraffin. 
 
SOLUTIONS 
Acetate buffer, pH3.6 
Sodium acetate   : 4.1 g 
Acetic acid   : 6.25 ml 
Distilled water   : 500ml 
1% silver nitrate in pH 3.6 acetate buffer. 
 
DEVELOPER 
Dissolve 3 g of hydroquinone in 10ml pH 3.6 buffer, and mix 1ml of this 
solution and 15 ml of warmed 5% scotch glue or gelatin; keep at 40oC. Take 3 ml of 
2% silver nitrate in pH 3.6 buffer solution and keep at 55oC Mix these two solutions 
immediately before use. 
 
METHOD 
1. Deparaffinize and rehydrate through graded alcohols to distilled water. 
2. Celloidinize in 0.5% celloidin, drain and harden in distilled water, 1 min. 
3. Impregnate in pre-heated 55-60oC silver solution (b), 90-105 minutes. 
4. Prepare and preheat developer in a water bath. 
5. Treat with developer (solution c) for 31/2 minutes at 55oC. Sections should 
be golden-brown at this point. 
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6. Remove from developer and rinse in tap water for several minutes at 55-
60oC, then buffer at room temperature. 
7. Tone in 0.2% gold chloride. 
8. Dehydrate, clear and mount. 
 
RESULTS 
Spirochetes : Black 
Background : Golden yellow 
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RESULTS 
 
Table :1  
 
1 Total Number of Cases 150 
2 Total Number of Esophageal Biopsy 150 
3 Total Number of  Gastric Antral Biopsy 138 
 
Table :2  
 
GENDER DISTRIBUTION OF THE CASES 
Sl.No  Gender Number of Cases 
1 Male 102 (68%) 
2 Female 48(32%) 
 
Table :3 
 
AGE WISE PREVALENCE OF GASTROPHAGEAL REFLUX DISEASE AND 
GENDER DISTRIBUTION  
Sl.No.  Age Group 
(Years) 
No of cases Male Female 
1 0-10  - - - 
2 11-20  4 4 - 
3 21-30  25 15 10 
4 31-40  46 30 16 
5 41-50  25 17 8 
6 51-60  22 16 6 
7 61-70 16 11 5 
8 71 & above 12 9 3 
 Total 150 102 48 
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Table : 4 
        THE DIFFERENT TYPES OF ESOPHAGEAL LESIONS IN THE STUDY 
Sl.No. Type of Lesion Number of cases 
1 Chronic reflux esophagitis 88 
2 Barrett’s esophagus 46 
3 Vascular Ectasia 4 
4 Malignancy 12 
 
Table : 5 
MALIGNANT LESIONS 
Sl.No. Malignant Lesions Number of cases 
1 Squamous cell carcinoma  9 
2 Adenocarcinoma 3 
 
Table : 6 
HISTOLOGICAL GRADING OF BARRETT’S OESOPHAGUS 
Sl.No. Histological Grade Number  of cases 
1 Classical Barrett’s  39 
2 Low – Grade Dysplasia  4 
3 High- Grade Dysplasia  3 
 
Table : 7 
THE CORRELATION OF ESOPHAGEAL LESION (BIOPSY) 
 WITH H.PYLORI STATUS 
Sl.No. 
Type of Esophageal 
lesion 
Number of 
cases 
Number of cases 
Positive for 
H.Pylori 
1 Chronic reflux 
esophagitis 
88 34 (39%) 
2 Barrett’s oesophagus 46 16 (34%) 
3 Malignancy 12 0 
4 Vascular Ectasia 4 0 
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Table : 8 
 
VARIOUS GRADES OF BARRETT’S OESOPHAGUS HAVING 
 ASSOCATION WITH H. PYLORI  
Sl.no. 
Histological grade of Barrett’s 
oesophagus 
Number of 
cases 
H.Pylori 
Positive 
1 Classical Barrett’s  39 14 
2 Low – Grade Dysplasia 4 1 
3 High – Grade Dysplasia  3 1 
 
Table : 9 
GASTRIC ANTRAL BIOPSIES POSITIVE FOR H. PYLORI  
Sl.No. Biopsy Number of cases 
1 Total number of gastric biopsies  138 
2 Number of cases positive for H. Pylori  50 (32.6%) 
 
Table 10 : 
THE SEVERITY OF INFLAMMATION IN THE ANTRAL BIOPSIES  
AND ITS ASSOCATION WITH H. PYLORI  
Sl.No. Severity of Inflammation  Number of cases 
1 Mild Inflammation 37 (74%) 
2 Moderate Inflammation 10 (20%) 
3 Severe Inflammation  3 (6%) 
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DISCUSSION  
 In our study we have analysed the histomorphology of esophagus in 150 
patients, who presented  with symptoms of gastroesophageal reflux disease to the 
outpatient Department of Medical Gastroenterology and a private Medical 
Gastroenterology Clinic.  
 This study carries a unique significance as it was conducted in part of country, 
where people have different life styles, food and personal habits.  Most of the patients 
were from Tirunelveli and the two neighbouring coastal Districts of Thoothukudi and 
Kanyakumari.  
 The study population included both children and adults, however adults were 
predominant.  
 We had four children 2.6 (%) and one hundred forty six 97.4. (%)adults.  
(Wide Table 3.) This correlates with the study of Sonnenberg HB et al (1999), who 
found a significant rise in the number of children with symptoms of Gastroesophageal 
reflux Disease.  In most of the children in our study, the esophageal changes were that 
of reflux esophagits and we did not have even a single case of Barrett’s.  This 
observation differ from that of Robbins 7th Edition, who found out that reflux 
esophagits is occasionally seen in infants and children.  A much more large sample 
analysis will help us in to make a definite conclusion.  
 The peak age groups of patients implicated with symptoms of 
Gastroesophageal reflux disease were between 32-40 years of age, very much closer 
to the observation that reflux esophagitis is most common in the middle aged persons 
Anderson 10th edition.  (Wide Table No 3) 
The   incidence of Barrett’s   esophagus were found in individuals  of fourth or 
fifth decade and we had very few cases  within fourth decade.  None of the malignant 
 42
cases were seen in younger patients.  This is in coherence with the observation of 
Johnson DA and Fennerty MB (2004) who found out that increasing age is an 
important factor in the prevalence of Gastroesophageal reflux disease complications 
and they attritubuted  this to the cumulative acid induced injury to the esophagus over 
time.  
The gender distribution of the cases illustrated in Table No:2  We had 102,  
68(%) number of male patients and 48  female patients 32(%).  
This goes hand in hand with the observation made by various authors, who 
found that gastroesophageal reflux disease is almost equally seen in both gender, 
however the esophageal lesions of the gastroesophageal reflux disease were more 
common in men than in women.    
We tried to analyse the esophageal lesions with respect to the gender of the 
population under study.  (Wide table 2). We found out that the men had a higher 
number of reflux esophagitis and Barrett’s esophagus  than women. 68(%). This is 
similar to the observation made by Cecilia M. F who found that there is an 
unequivocal male predominance of reflux esophagitis and Barrett’s esophagus  
Regarding the common associated symptoms, most of our cases included in 
the study presented with heartburn which resembles the observation made by Nebel  
et al 1976 - 1977 who opined that heartburn is the most common and classical 
symptoms of Gastroesophageal reflux disease.   
In our study, we found that most of the patients expressed heartburn 
postprandially  especially after intake of spicy, fatty food.  Few of our cases had this 
symptom following intake of certain medications for headache and body ache.  
Analysis of the esophageal lesions reveal that the most common 
histomorpholgical changes  encountered  was that of Chronic reflux esophagitis     
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58.6(%) followed, by Barrett’s 29.3 (%) malignancies 8 (%) and few cases of 
miscellaneous changes like vascular ecstasias 2.6(%) This correlates well with similar 
observation made by other authors.  
 
Analysis of the various histomorphological features of esophagus in 
Gastroesophageal reflux Disease  
Epithelial hyperplasia with expansion of the basal zone and elongation  of the 
vascular papillae of the lamina propria was found in most of our cases of Chronic 
reflux esophagitis. This correlates well with the observation made by Collins BJ et al 
(1996) who was of the opinion that epithelial hyperplasia indicated a rapid epithelial 
turnover and proliferation, was a very significant histological change seen in patients 
with chronic reflux esophagitis. They called this change as a marker of reflux.  
Balloon degeneration of the epithelial cells is found to be yet another indicator 
of epithelial cell injury. The epithelial cells appear swollen, rounded with pale 
staining cytoplasm.  
Jessurun JY etal (1988) proposed that the presence of these balloon cells 
indicates epithelial cell injury.  
We also had many cases, showing balloon degeneration of the squamous 
epithelium.  42 cases of the total 88 cases Chronic reflux esophagitis showed the 
presence of balloon cells.  This correlates well with the observation of Sternberg vol 2 
– Vth  edition who found that two thirds of the patients  with Chronic reflux 
esophagitis  showed presence of balloon cells in the epithelium.  
Presence of a markedly dilated lamina propria, with elongated vascular 
papillae and congested capillaries is yet another finding seen in cases of 
Gastroesophageal reflux disease, Geboes K etal (1980).  Most of our cases of Chronic 
reflux esophagitis  showed elongated vascular papillae with congested lamina propria.  
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Presence of intra epithelial eosinophils is an additional indicator of 
Gastroesophageal reflux disease, Tummala V. et al (1987)  
Haggi HC (2000) found out that significance could be given to it when more 
than six eosinophits were present in the specimen.  Brown etal (1984) found out, the 
presence of eosinophils within the epithelium was the most frequent abnormality seen 
in cases of Chronic reflux esophagitis  .    
In this present study, only few of our cases with Chronic reflux esophagitis    
showed presence of eosinophils within the epithelium.  In our study 18 cases of total 
88 cases showed significant presence of intra epithelial eosinophils.  
Barrett’s Esophagus 
 In Barrett’s esophagus the squamous cell epithileum has undergone 
metaplastic chage to columar epithelium, presumably as a result of long standing  
gastro-esophageal reflux. Spechler  SJ and Goyal RK (1986).  
The transformed mucosa may have a foveolar, some times a villous pattern 
with irregular crypts and glands. The metaplastic epithelium mainly consists of 
columnar cells and goblet cells. Few neuroendorine cells and paneth cells may be 
present. 
 In our study, we had 46 patients presenting with Barrett’s Esophagus. In most 
of them, the metaplastic epithelium was made up of columar cells, resembling the 
gastric mucous cells. 
 Inflammation was not very significant in the cases of Barrett’s Esophagus. We 
had noticed non-specific inflammation in 7(15%) of our cases and ulceration was seen 
only in 2 cases 4(%). This is in coherance  with the observation  made by Petras  RE 
et al (1991), who found that ulceration and inflammation are non-specific changes 
seen in association with Barrett’s esophagus. 
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Dysplasia and Barrett’s esophagus: 
Although all patients with Barrett esophagus are at increased risk, certain 
patients are at higher risk than others. Most Patients with Barrett esophagus – 
associated adenocarcinoma are older white men (Falk G.W 2002). As previously 
mentioned, there is also evidence to support the contention that only those patients 
with goblet cells are at increased risk of developing adenocarcinoma  (Hamilton SR et 
al 1987) 
Barrett’s esophagus have 30-40 fold increased risk for esophageal 
adenocarcinoma. The development of an adenocarcinoma appears to be preceded by 
the presence of epithelial dysplasia. Several longitidunal follow up studies have 
clearly documented the gradual increase in the severity of dysplasia leads to increased 
risk of adenocarcinoma. These observations suggest that the dysplastic changes might 
be taken as early indicator of incipient malignancy. 
Dysplasia can be defined as the presence of neoplastic epithelium confined 
within the basement membrane of the gland from which it arises  (Riddell R.H et al 
1983) 
 Dysplasia in Barrett’s esophagus is classified into low or high grade in a  
fashion comparable to the dysplasia in inflammatory bowel disease, Riddell RH et al 
(1983). This implies that the grade of dysplasia should be determined by the features 
of the most dysplastic region, either surface or base. 
 
 The criteria for grading the dysplasia in Barrett’s esophagus has been laid by 
Haggitt RC (1994). In low grade dysplasia the crypt architecture is preserved with 
overcrowding of the nuclei near the base of the crypt. Goblet cell numbers are often 
reduced and dystrophic goblet cells may be present. whereas in high grade dysplasia 
the distortion of the crypt architecture is marked and is composed of  branching 
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crypts. The epithelium is arranged back to back with loss of nuclear polarity. 
(Cameron AJ and carpenter HA (1997). 
In some cases, the distinction between high – grade dysplasia and 
intramucosal adenocarcinoma (defined by the penetration of neoplastic cells through 
the basement membrane to infiltrate into the lamina propria or muscularis mucosae) 
may be difficult, particularly in a biopsy specimen (Ormsby A.H et al 2002) 
Because of its metaplastic nature, the glands at the base of Barrett Mucosa 
show “baseline atypia” characterized by enlarged, slightly hyper chromatic cells with 
some stratification and increased mitotic activity. Thus, cytologic atypia involving the 
surface epithelium is a major diagnostic criterion for making a definitive diagnosis of 
dysplasia.   
 
 In our present study we had 7 cases of dysplasia seen out of 46 cases of 
Barrett’s esophagus. Of these 4 were typed as low grade dysplasia and 3 as high grade 
dysplasia, (Table 6). 
 
 These cases are being placed under close followup to observe any significant 
malignant transformation, especially the cases with high grade dysplasia. Weston AP 
et al (2000) found that about 53% of the patients with high grade dysplasia progressed 
to multifocal high grade dysplasia or an invasive carcinoma. 
 In contrast, a large study of patients with Barrett – related  high – grade 
dysplasia suggested that surveillance endoscopy with biopsy is a valid and safe    
follow – up strategy for patients with high – grade dyplasia without concurrent cancer 
since only 16% of patients subsequently developed carcinoma during a mean 
surveillance period of 7.3 years (Schnell TG et al 2001) 
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 Burke et al (1991) was of the opinion that low grade dysplasia is rather 
indolent and a not a reliable hall mark for malignancy. 
GERD and malignancy: 
 Out of the 150 cases included in our study we found out malignant lesion in 12 
cases (8%). The endoscopic picture was classical in 8 of the cases with ulcerated, 
ulceroproliferative lesion, whereas in the other 4 the endoscopic picture was not 
classical. Multiple biopsies were taken in suspicion to exclude a malignancy. 
 Histological analysis of cases of malignancies showed 9 cases (75%) of 
squamous cell carcinoma and 3 cases (25%) of adenocarcinoma. (Table No 5) 
 This is comparable to the observation made by Souza R.F (2002), who found 
that occurrence of squamous cell carcinoma was the most common type of carcinoma 
followed by adenocarcinoma. Out of the nine cases 7 elderly individuals belong to 5th 
decade and above. We had 2 cases of esophageal squamous cell  carcinoma present in 
the third decade. Both these  patients were found to be chronic alcoholics with a long 
history of cigratte smoking. They also had histomorphological  features of chronic 
esophagitis in the non malignant area, suggesting the fact that it could have been a 
trigger for the malignant transformation. 
 Regarding the site and distribution of squamous cell carcinoma, 5 cases had 
lesion in the mid esophagus and the rest 4 had a lesion in the lower esophagus. All of 
them presented with ulcerative type of lesion. Histologically they were categorised 
between well differentiated squamous cell carcinoma  to moderately differentiated 
squamous cell carcinoma. 
 In this present study, we had 3 cases of adenocarcinoma of esophagus. Which 
constitutes 25% of total malignancies seen in our study. In all the three cases there 
was  evidence  of Barrett’s esophagus with ulceration, in fact in all of them the 
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endoscopy findings were that of ulcerated Barrett’s esophagus. Histologically the 
diagnosis of adenocarcinoma was made. Two of the three cases had feature of high 
grade dysplasia in addition to the malignancy and in the other cases  we could not find 
any evidence of dysplasia. This goes hand in hand with the observation made by 
several workers that majority of adenocarcinoma arise from pre-existing Barrett’s 
Esophagus. (Blot W et al (1993)). In all the three cases, the lesion was located in 
distal esophagus with infiltration into gastric cardia. Histomorphologically all the 
three cases were well differentiated adenocarcinoma. 
 
H-pylori and GERD 
Another aspect of our study was to determine the prevalence of gastric 
H.pylori infections in patients with esophageal lesions of GERD. To achieve this, 
concomitant gastric antral biopsies were taken when the patient was subjected to 
upper GI endoscopy. Out of the total 150 cases, we were able to obtain gastric, antral 
biopsy samples for 138 cases. (Wide Table 1) 
 The gastric antral biopsy was analysed for the type of inflammatory reaction 
according to modified Sydney system of classification and were broadly grouped into 
mild, moderate and severe. (Wide Table10) 
 Warthin starry silver stain was used to detect the presence of H.pylori and it 
was noted as positive or negative. (Wide Table 9) 
 The histomorphology of the esophageal lesions were kept blind folded during 
the evaluation of the gastric antral biopsies to avoid bias in observation. 
 Out of the total 138 antral biopsies, H.pylori was detected in 50 number of 
cases (32.6%). H.pylori was not detected in 88(63.7%) number of cases. 
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 The presence of H.pylori status was then compared  with that of the 
esophageal histomorphology. 
 Chronic reflux esophagits was the most common esophageal lesion studied, 
and we had 88 cases of the total 150 cases. H.pylori was detected in 34 of the total 88 
cases with Chronic reflux esophagitis . (39%). This correlates very well with similar 
observation made by Abbas Z et al (1995) who found 38% of positivty in their study 
of 29 cases. They found a equal positivity among patients with Chronic reflux 
esophagitis  and Barrett’s Esophagus. 
 The values of our study is slightly lower than that observed by Weston AP et 
al (2000), who found 44.2% of their cases with Chronic reflux esophagitis, had gastric 
H.pylori infection. 
 Newton  M et al (1997) also had a very similar observation like ours. In his 
study on subjects with GERD he found 36% of the cases of Chronic reflux esophagitis   
had gastric H.pylori. 
 Barrett’s esophagus was the second common lesion observed in our study. The 
prevalence of gastric H.pylori was analysed for the patients presenting with Barrett’s 
esophagus. 
 In our study we found 34% of the patients presenting with Barrett’s esophagus 
had gastric H.pylori infection. This observation matches well with that of Abbas. Z et 
al loc cit (1995)  who found  an incidence of 39%. He also analysed the presence of 
H.pylori in the columnar mucosa of Barrett’s esophagus Weston AP et al (2000)             
had an observation very similar to our study. He was able to demonstrate the presence 
of H.pylori in 95 of the total 289 cases. (32.9%). He found a positivity of 44.2% in 
cases of Chronic reflux esophagitis. 
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 Newton M et al and his colleagues in a similar study found about 25% of the 
cases were positive for H.pylori. Henihan RD et al (1998) came out with a positivity 
of 23% (19 out of 82 patients) with  Barrett’s esophagus. He was not able to detect the 
organism in cases of adenocarcinoma of esophagus. 
 Gebrud D et al (1998) evaluated the incidence of gastric H.pylori infection in 
patients with Barrett’s esophagus and found that 39% (11 out of 28 cases) had gastric 
H.pylori infection. 
 Peitz V et al (1997) had a higher incidence of positivity with 50% of the total 
cases showing the presence of gastric H.pylori. 
 A prospective study by Lord RV et al (2000) revealed a gastric H.pylori 
positivity of 31.3% in cases of Chronic reflux esophagitis and 16.5% in cases of 
Barrett’s esophagus. He was of the opinion that gastric H.pylori infection may have a 
protective effect for the development of Barrett’s esophagus. 
The incidence of Helicobacter pylori infection in the patients with  
Gastroesophageal reflux disease , varies widely in literature from 30% to 90% and 
approximatemy of 35% in most series .  
Various studies have been done to detect the prevalence of gastric H.pylori 
infection in gastroesophageal reflux disease.  In USA , Cheng  found  out that , of the 
27 gastroesophageal reflux disease patients, 41% of them had H. pylori positivity .  In 
his study, he established the presence of H. pylori by means of demonstration   of the 
organism in antral mucosal histology, culture and urease activity. Whereas Abbas in 
his study done at Pakistan, found it to be higher. He found that 62% of the 
gastroesophageal reflux disease patients where positive for H. pylori infection .  
Similarly Liston, who carried out his work at UK also found an increased percentage  
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of H. pylori positive gastroesophageal   reflux disease patients.  He fount that up to 
76%. of  them where infected with H. pylori.  In his study, he utilized Serology also to 
establish the presence of H. pylori . In our study we found that the association was 
less. We utilized the antral mucosal  histology and Warthin starry stain to demonstrate 
the presence of H. pylori infection.  Our study showed that 30% of the 
gastroesophageal reflux disease patients, were infected with H. Pylori.  This correlates 
well with the various other studies done by others  in various parts of the world.   
However in another study done by Grande et al (2008), he found no significant 
evidence for an important role for H. pylori infection in the development of 
gastroesophageal   reflux disease and erosive esophagitis. 
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Table 11 
 
The following table summarises the result of various studies in  
the prevalence of gastric H. Pylori in GERD.  
 
 
 
 
Authors Geographic area 
Number 
of GERD 
patients 
% of 
H.pylori 
positive 
Method of 
establishment of 
H.Pylori 
Cheng USA 27 41% 
Antral mucosal Histology 
Culture   
Urease activity  
Abbas Pakistan 29 62% Antral mucosal Histology  
Liston UK 37 76% Antral mucosal Histology Urease activity Serology 
Werdmuller Netherlands 118 29% 
Antral mucosal Histology 
Urease activity 
Serology 
Newton UK 36 36% 
Antral mucosal Histology 
Urease activity 
Serology 
Varanasi USA 114 31% Antral mucosal Histology Rapid Urease 
Hackelsberger Germany 130 39% 
Antral mucosal Histology 
Rapid Urease 
Serology 
Vicari USA 84 36% Antral mucosal Histology Serology 
Wu Hongkong 106 31% 
Antral mucosal Histology 
Urease activity 
Serology 
Maves Italy 110 40% Antral corpus Histology Serology 
Koike Japan 175 34% 
Antral mucosal Histology 
Corpus Histology 
Urease activity 
Serology 
Wu China 225 34% 
Antral mucosal Histology 
Corpus Histology 
Urease activity 
Serology 
Our Study India 150(50) 30% Antral mucosal Histology Warthins –starry 
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Table 12 
 
PREVALENCE OF H.PYLORI IN CASES OF BARRETT’S ESOPHAGUS 
The following table summarises the results of various studies on the 
prevalence of gastric H.Pylori infection in cases of Barrett’s esophagus. 
 
Authors 
Geographical 
area 
No of cases 
of  Barrett’s 
esophagus 
% of HP 
positive 
Method of establishment of 
H. Pylori infection 
Paull USA 26 39% Antral mucosal Histology 
Abbas Pakistan 29 48% Antral mucosal Histology 
Werd 
Muller 
Netherlands 13 23% 
Antral mucosal Histology 
Csendes Chile 100 20% Antral mucosal Histology 
Newton UK 16 25% 
Antral mucosal Histology  
Urease activity 
Vicari USA 48 31% Urease activity 
Oberg Sweden 40 13% Antral mucosal Histology  
Schenk Netherlands 49 20% Antral mucosal Histology  
Westen USA 289 33% Antral mucosal Histology  
Our 
study 
India 46 34% 
Antral mucosal Histology  
Warthins starry stain 
 
Both GERD and H.pylori colonization are, common phenomenon.  Their 
different geographical distribution is a first hint that H.Pylori may be negatively 
assocated with GERD.  
 An analysis of the findings given in the table suggests a lower prevalence of 
gastric H. Pylori infection in patients with endoscopic signs of GERD.  
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 GERD patients with concomitant H.Pylori infection showed more severe 
gastritis in the antrum than in other parts of the stomach, such as corpus, fundus and 
cardia.  
Apart from a lower prevalence of GERD among H.Pylori positives, some also 
reported that if GERD is present in  H.Pylori positive subjects it may be less severe . 
These observations have been made against the background of changing time 
trends in the prevalence of H. pylori and the incidence of GERD and GERD 
complications.  As mentioned, the prevalence of H. pylori in Western countries has 
steadily decreased in the past decades as a result of socio-economic changes.  This has 
led to a significant drop in the incidence of H. pylori-associated disorders such as 
peptic ulcer disease and adenocarcinoma of the distal stomach. (El-Serag HB et al 
1997)  In the  same period however, the incidence of GERD and GERD complications 
such as Barrett’s esophagus and adenocarcinoma of the gastro-esophageal junction 
has increased four-to seven-fold (Blaser MJ 1997).  
Reflux disease  results from intreaction between acid  production, lower  
esophageal sphincter pressure, esophageal clearance and gastric emptying. H. Pylori 
may affect several of these factors.  Few individvals respond to H. Pylori colonization 
with and exaggerated gastric response leading to increased acid production.  These 
individuals are at the risk of developing duodendal ulcer disease and reflux disease.  
Gastric acid production is impaired due to several factors, including the 
realease of substances such as the VacA protein, which directly inhibits parietal cell 
function and bacterial urease activity generating large amounts of acid – buffering 
ammonia.  As a result of these factors, H. Pylori gastritis extends into the gastric 
corpus where mucosal inflammation further impairs acid production, among others by 
the generation of interleukin – 1, which has a 100-fold stronger acid – suppressive 
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capacity than proton pump inhibitors.  Most importantly however, more than 50% of 
the H. pylori positive subjects eventually develop chronic atrophic gastritis.  This 
results in a loss of parietal cells and thus a further impairment of acid production.   
(Kuipers EJ et al 1995). These factors which lead to a persistent decrease in acid 
production can explain why H. Pylori may protect against GERD.  
 Therefore epidemiological data  strengthen the idea that the H. Pylori protects 
against GERD developments through the induction of atrophic gastritis.  
 Schenk etal (1999) observed in a prospective endoscopical study that H. Pylori 
negative patients had a higher incidence of Barrett’s esophgagus than H. Pylori 
positive GERD patients.  We also had a   similar observation in our study in which the 
H. Pylori positivity was lower in Barrett’s and it was absent in cases of  
adenocarcinoma.  
 Kiltz U et al (2000) in his study concluded that the presence of H. Pylori might 
delay the development of Barrett’s esophagus, which could explain the lower 
positivity rate of H. Pylori positivity in cases of BE.  
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SUMMARY  & CONCLUSION 
 
 Barrett’s esophagus is seen in a younger population amongst Indians.  A male 
predominance is noted.   There is a paucity of patients with pure dysplasia in Barrett’s 
metaplasia.  Despite the fact that there are a number of patients presenting with 
Barrett’s esophagus and carcinoma, very few patients present with dysplasia, 
indicating that Barrett’s esophagus is a silent disease presenting later as a carcinoma.  
In summary, the cumulative data support the hypothesis that reduction of acid 
output by pharmaceutical agents or vagotomy induces and increase of corpus gastritis 
in H. Pylori positive patients, which leads to further reduction of acid accelerates 
development of corpus atrophy.  Because of the latter phenomenon, H. Pylori 
eradication has been suggested for younger H. Pylori – positive patients in need of 
PPI maintenance therapy for GERD.  Such a strategy does not seem to have an effect 
on the efficacy of such therapy, but long-term prospective studies have to show that it 
prevents the development of atrophic gastritis.  
 H. Pylori colonization is very common among humans, with individual strains 
showing clear variations in pathogenetic properties all H. Pylori positive subjects have 
chronic active gastritis.  H. Pylori colonization and associated gastritis strongly 
interact with gastric acid production.   
 The evidence is accumulating that in particular the latter pattern of H. Pylori 
colonization protects against GERD.   This hypothesis is supported by the finding of a 
low H. Pylori prevalence, in particular of the cagA- positive type, in GERD patients 
and patients with GERD complications.  
 H. pylori not only plays a role in the etiology of GERD, but also in the 
treatment of GERD.  
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 The presence of H. Pylori corpus gastritits augments the effects of acid 
suppressive medication, in particular of proton pump inhibitors.  This may have some 
effect during the initial treatment, where some suggest that H. Pylori positive patients 
show a somewhat quicker healing and symptom reduction than H. Pylori – negative 
patients.  During maintenance therapy however, H. Pylori has little effect on the 
efficacy of Proton-pumb inhibitors (PPI)  therapy and H. Pylori – positive and 
negative patients require similar does of PPI. However, in this phase the ongoing 
profound acid suppression facilitates the persistent presence of a more prominent 
chronic active body gastritis.  This accelerates the progression to gland loss or 
atrophic gastritis.  This effect can be prevented by H. pylori eradication in those who 
need maintenance PPI treatment for GERD.  Although the long – term consequences 
of this phenomenon still have to be elucidated further H. Pylori eradication should 
currently be considered in younger H. pylori – positive GERD patients requiring 
maintenance PPI therapy.  
Master Chart 
SL.No. Biopsy No Name Age Sex Esophageal Biopsy  Antral Biopsy H.Pylori status  
1 1832 K.R. Subramanian 71 M Barrett’s esophagus Mild Inflammation  Positive  
2 1830 R. Kausalya 36 F Barrett’s esophagus Mild Inflammation  Positive  
3 1826 Natarajan 35 M Barrett’s esophagus Mild Inflammation  negative   
4 1851 Nataraja Palani 36 M Barrett’s esophagus Mild Inflammation  negative   
5 1903 Master Amith Raj 12 M Barrett’s esophagus Mild Inflammation  negative   
6 1952 Antony Ganana Henson 25 M Chronic reflux esophagitis Mild Inflammation  Positive  
7 1812 Murugan 34 M Barrett’s esophagus Mild Inflammation  Positive 
8 1791 Prem 34 M Barrett’s esophagus Mild Inflammation  negative   
9 1789 Angeline 49 F Chronic reflux esophagitis Mild Inflammation  Positive 
10 1775 Chellammal 58 F Chronic reflux esophagitis Moderate Inflammation  Positive   
11 1773 Subramanian 22 M Chronic reflux esophagitis Mild Inflammation  negative   
12 1741 Andiappan 33 M Barrett’s esophagus Mild Inflammation  negative   
13 1739 Kalayana Sundaram 40 M Barrett’s esophagus Mild Inflammation  Positive  
14 1680 Fathimuthu 65 F Barrett’s esophagus Mild Inflammation  Positive  
15 1677 Suganthi 57 F Chronic reflux esophagitis Mild Inflammation  Positive  
16 1654 Livingston 47 M Barrett’s esophagus Mild Inflammation  Positive  
17 1652 Muthukrishnan 48 M Chronic reflux esophagitis Mild Inflammation  Negative  
18 1593 Marthan 63 M Chronic reflux esophagitis Mild Inflammation  Positive  
19 1591 Rajmohan 47 M Chronic reflux esophagitis Mild Inflammation  Negative 
20 1589 Sivasethuramalingam 74 M Well differentiated squamous 
cell carcinoma  
Mild Inflammation  Negative 
21 1630 Maheshwaran 35 M Barrett’s esophagus Mild Inflammation  Positive 
22 1628 Razool Nisha 44 F Chronic reflux esophagitis Mild Inflammation  Negative  
23 1625 Absarkhan 40 M Barrett’s esophagus Mild Inflammation  negative   
24 1559 Abdul Kayam  34 M Barrett’s esophagus Mild Inflammation  Positive  
25. 1534 SeethaLakshmi 32 F Barrett’s esophagus Mild Inflammation  Positive 
26 1532 Ramesh 37 M Chronic reflux esophagitis Mild Inflammation  negative   
27 1397 Vinodh 20 M Chronic reflux esophagitis Mild Inflammation  negative   
28 1395 Murugesan  48 M Barrett’s esophagus Mild Inflammation  Positive  
29 1402 Gangadharan 37 M Chronic reflux esophagitis Mild Inflammation  negative   
30 1400 Muruganandham 47 M Barrett’s esophagus Mild Inflammation  Positive  
31 1756 Raja Ramalingam 74 M Barrett’s esophagus Mild Inflammation  Positive  
32 1745 Radhakrishnan 58 M Barrett’s esophagus Mild Inflammation  Positive  
33. 2201 MuthuBala 25 M Chronic reflux esophagitis Mild Inflammation Negative  
34. 2732 Murugan 40 M Barrett’s esophagus Mild Inflammation  negative  
35 2691 Mohammed Subair 26 M Chronic reflux esophagitis Mild Inflammation negative  
36 5978 Ganesh Babu 31 M Chronic reflux esophagitis Mild Inflammation negative  
37 5889 Gomathy 39 F Chronic reflux esophagitis Mild Inflammation negative  
38 6512 Thilagavathy 31 F Barrett’s esophagus Mild Inflammation  negative   
39 6489 Kamalakannan 30 M Barrett’s esophagus Mild Inflammation  Positive 
40 6467 Subbiah Thevar 63 M Chronic reflux esophagitis Mild Inflammation Positive  
41 3891 Mohammed Isaque 37 M Barrett’s esophagus Mild Inflammation  Positive   
42 7980 Pandian 24 M Chronic reflux esophagitis Mild Inflammation negative   
43 2663 Biswas 38 M Chronic reflux esophagitis Mild Inflammation  Positive   
44 2187 Sumaitha Beevi 33 F Vascular Ectasia Mild Inflammation  Negative  
45 2663 Chidambaranthan 22 M Chronic reflux esophagitis Mild Inflammation  Negative  
46 2267 Mariappan 38 M Chronic reflux esophagitis Mild Inflammation  Positive   
47 2637 Appasamy 32 M Barrett’s esophagus Mild Inflammation  Positive   
48 2515 Chandrasekaran 36 M Barrett’s esophagus Mild Inflammation  Negative  
49 2332 Abdul Hussain 29 M Chronic reflux esophagitis Mild Inflammation  Negative  
50 2335 Mohammed Aneez 18 M Barrett’s esophagus Mild Inflammation  Negative  
51 2334 Saravanan  28 M Barrett’s esophagus Mild Inflammation  Negative  
52 2245 Padamsena 66 M Chronic reflux esophagitis Mild Inflammation  Positive   
53 2201 Mithunsekar 25 M Chronic reflux esophagitis Mild Inflammation  Positive   
54 2162 Shenbagavalli 27 F Chronic reflux esophagitis Mild Inflammation  Positive   
55 2140 Senthilkumar 31 M Chronic reflux esophagitis Mild Inflammation  Positive   
56 2090 Kanchanadevi 42 F Chronic reflux esophagitis Mild Inflammation  Positive   
57 2092 Ganesan 39 M Chronic reflux esophagitis Mild Inflammation  Positive   
58 2094 Chandrasekar 49 M Barrett’s esophagus Mild Inflammation  Positive   
59 2096 Mohan 34 M Barrett’s esophagus Mild Inflammation  Positive   
60 2042  Chelladurai 29 M Chronic reflux esophagitis Mild Inflammation  Negative  
61 2020 Muthukrishnan 29 M Barrett’s esophagus Mild Inflammation  Negative  
62. 2022 Jaikannan 20 M Vascularectasia Mild Inflammation Negative  
63. 2001 Gopalakrishan  50 M Chronic reflux esophagitis Moderate Inflammation  Negative 
64 2003 Rangasamy 53 M Barrett’s esophagus Moderate Inflammation  Positive 
65 1989 Ramanarayanan 80 M Poorly differentiated  squamous 
cell  carcinoma 
Mild Inflammation Negative 
66 3421 Kothai 54 F Barrett’s esophagus Moderate Inflammation  Positive 
67 3424 Baskar 37 M Squamous cell carcinoma Moderate Inflammation Negative 
68 3428 Vijayan 22 M Barrett’s esophagus Mild Inflammation  Negative 
69 3404 Susiladevi 37 F Chronic reflux esophagitis Mild Inflammation  Negative  
70 3408 Prabhukannan 27 M Barrett’s esophagus Mild Inflammation  Negative 
71 3410 Sabiral 48 F Barrett’s esophagus Mild Inflammation  Negative 
72 3412 Marimuthu 34 M Chronic reflux esophagitis Moderate Inflammation  Negative  
73 3366 Fairose Begum 35 F Barrett’s esophagus Mild Inflammation  Negative 
74 3326 Irshad  35 M Chronic reflux esophagitis Mild Inflammation  Negative  
75 3221 Niyaz 25 M Chronic reflux esophagitis Mild Inflammation  Negative  
76 3223 Manikandan 26 M Barrett’s esophagus Mild Inflammation  Positive  
77 3226 Basheer 40 M Chronic reflux esophagitis Mild Inflammation  Positive 
78 3230 Gothandapandi 41 M Barrett’s esophagus Mild Inflammation  Negative  
79 3166 Muthulakshmi 27 F Chronic reflux esophagitis Mild Inflammation  Negative 
80 3168 Jegadesan 42 M Barrett’s esophagus Mild Inflammation  Positive  
81 2975 Soundarakumari 58 F Chronic reflux esophagitis Mild Inflammation  Negative 
82 2978 Albet 49 M Barrett’s esophagus Mild Inflammation  Positive  
83 3129 Ramakrishan 28 M Vascular Ectasia Mild Inflammation  Negative  
84 3130 Thirumalaikumar 28 M Barrett’s esophagus Mild Inflammation  Positive  
85 3066 Selvarajan 67 M Chronic reflux esophagitis Mild Inflammation  Positive 
86 3069 Latha 40 F Barrett’s esophagus Mild Inflammation  Negative 
87 3030 Thangam 59 F Chronic reflux esophagitis Mild Inflammation  Negative 
88 3034 Maharajan 27 M Barrett’s esophagus Moderate Inflammation  Negative 
89 2837 Muthupandi 36 M Adenocarcinoma Mild Inflammation  Negative 
90 2839 Murugan 46 M Chronic reflux esophagitis Mild Inflammation  Positive 
91 2843 Michael  22 M Barrett’s esophagus Mild Inflammation  Negative 
92 2739 Vellathai 35 F Vascular ectasia Mild Inflammation Negative 
93 1828 Pannerselvan 34 M Chronic reflux esophagitis Mild Inflammation  Negative 
94 1827 Balasubramanian 40 M Chronic reflux esophagitis Mild Inflammation  Positive 
95 1853 Subbulakshmi 34 F Chronic reflux esophagitis Mild Inflammation  Negative  
96 1852 Shahul Hameed 41 M Chronic reflux esophagitis Mild Inflammation  Negative 
97 1901 Irduaya Felo 71 M Squamous cell carcinoma Mild Inflammation Negative 
98 1900 Majeed 72 M Adeno carcinoma Mild Inflammation Negative 
99 1898 Ranjitham 45 F Chronic reflux esophagitis Mild Inflammation  Negative 
100 1897 Janaki 75 F Squamous cell carcinoma Mild Inflammation Negative 
101 1922 N. Prasad 14 M Chronic reflux esophagitis Mild Inflammation  Negative 
102 1920 B. Roy 30 M Chronic reflux esophagitis Mild Inflammation  Negative 
103 1954 Maridurai 43 M Chronic reflux esophagitis Mild Inflammation  Negative 
104 1953 Kumarasamy 49 M Chronic reflux esophagitis Mild Inflammation  Negative 
105 1815 ArulRani 37 F Chronic reflux esophagitis Mild Inflammation  Negative 
106 1814 Sankari 18 F Chronic reflux esophagitis Mild Inflammation  Negative 
107 1813 Annadurai 75 M Adenocarcinoma  Mild Inflammation Negative 
108 1810 Banu 38 F Chronic reflux esophagitis Mild Inflammation  Negative 
109 1792 Seetha 35 F Chronic reflux esophagitis Moderate Inflammation  Negative 
110 1776 Esakki 35 M Chronic reflux esophagitis Severe 
Inflammation  
Negative 
111 1737 Sulochana 58 F Chronic reflux esophagitis Mild Inflammation  Negative 
112 1678 Abdul Wahab 25 M Chronic reflux esophagitis Mild Inflammation  Negative 
113 1655 Babu 28 M Chronic reflux esophagitis Mild Inflammation  Positive  
114 1594 Rajalakshmi 67 F Chronic reflux esophagitis Severe Inflammation  Negative 
115 1627 Velusamy 38 M Barrett’s esophagus Moderate Inflammation  Negative 
116 1561 Ranjit 38 M Barrett’s esophagus Mild Inflammation  Positive 
117 1560 Noorul Ameer 56 M Chronic reflux esophagitis Severe Inflammation  Negative 
118 1551 Dhakshina Moorthy 77 M Squamous cell carcinoma Mild Inflammation Negative 
119 1556 Thirumalaikumar 34 M Chronic reflux esophagitis Mild Inflammation  Negative 
120 1555 Petchiammal 38 F Chronic reflux esophagitis Mild Inflammation  Negative 
121 1453 Fathemia Remosa 28 F Chronic reflux esophagitis Mild Inflammation  Negative 
122 1452 Antonyammal 54 F Chronic reflux esophagitis Moderate  Inflammation  Negative 
123 1451 Hajarmuthu 52 M Chronic reflux esophagitis Mild Inflammation  Negative 
124 1450 Mookammal 47 F Chronic reflux esophagitis Mild Inflammation  Negative 
125 1535 Fathima 27 F Chronic reflux esophagitis Mild Inflammation  Negative 
126 1530 Vijayakumari 31 F Chronic reflux esophagitis Mild Inflammation  Positive 
127 1495 Mohammed  66 M Squamous cell carcinoma Mild Inflammation Negative 
128 1494 Pitchaiah 47 M Chronic reflux esophagitis Mild Inflammation  Negative  
129 1492 Leelavathy  46 F Chronic reflux esophagitis Mild Inflammation  Negative 
130 1491 Vasantha 48 F Chronic reflux esophagitis Severe  Inflammation  Negative 
131 1379 Radha 29 F Chronic reflux esophagitis Mild Inflammation  Negative 
132 1378 Thiruvaranga Selvi 34 F Chronic reflux esophagitis Mild Inflammation  Positive 
133 1377 Manikandan 28 M Chronic reflux esophagitis Mild Inflammation  Negative 
134 1398 Viondh 25 M Chronic reflux esophagitis Mild Inflammation  Negative 
135 1394 Pattu Navoraj 51 F Chronic reflux esophagitis Mild Inflammation  Negative 
136 1114 Muthu Ramalingam 57 M Chronic reflux esophagitis Mild Inflammation  Negative 
137 2181 Sunitha Beevi 33 F Chronic reflux esophagitis Mild Inflammation  Negative 
138 2171 Habina Ummara 73 F Squamous cell carcinoma Mild Inflammation Negative 
139 2751 Sivagnanam 34 M Chronic reflux esophagitis Mild Inflammation  Negative 
140 2741 Ganesapandi 36 M Chronic reflux esophagitis Mild Inflammation  Negative 
141 2701 Mohan 49 M Chronic reflux esophagitis Mild Inflammation  Negative 
142 3001 Barani 44 F Chronic reflux esophagitis Mild Inflammation  Positive 
143 2951 Alagamuthu 39 M Chronic reflux esophagitis Mild Inflammation  Positive  
144 2941 Subaidhar 69 M Squamous cell carcinoma Mild Inflammation Negative 
145 2931 Ajay 25 M Chronic reflux esophagitis Mild Inflammation  Positive  
146 2921 Jayasekaran 46 M Chronic reflux esophagitis Mild Inflammation  Negative 
147 6531 Barakath Fathima 39 F Chronic reflux esophagitis Mild Inflammation  Negative 
148 2446 Soosan 49 F Chronic reflux esophagitis Mild Inflammation  Negative  
149 2412 Sabeena 45 F Chronic reflux esophagitis Mild Inflammation  Negative  
150 2367 Pavithra 25 F Chronic reflux esophagitis Mild Inflammation  Positive 
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